Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Marek Rodzaj"'
Publikováno v:
Acta Haematologica Polonica. 53:201-206
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da64ccf09aa653a7d5d44bf08709ec16
https://doi.org/10.5603/ahp.a2022.0024
https://doi.org/10.5603/ahp.a2022.0024
Autor:
Grzegorz Helbig, Martyna Włodarczyk, Iwona Hus, Wladyslaw Gawel, Anna Łabędź, Małgorzata Raźny, Marek Rodzaj, Anna Koclęga
Publikováno v:
Indian Journal of Hematology & Blood Transfusion
Systemic mastocytosis (SM) is a rare clonal disorder with multi-organ involvements and shortened life expectancy. To date, no curative treatment for SM exists. Cladribine (2-CdA) is a purine analogue showing activity against neoplastic mast cells and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85d552e8a18cc67aa2e2162585e8bc31
http://europepmc.org/articles/PMC7572963
http://europepmc.org/articles/PMC7572963
Autor:
Grzegorz, Helbig, Krzysztof, Lewandowski, Alina, Świderska, Marek, Rodzaj, Ilona, Seferyńska, Justyna, Gajkowska-Kulik
Publikováno v:
Polish archives of internal medicine. 130(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::089b2e1f39dcb41f09a48853d01dc5e0
https://pubmed.ncbi.nlm.nih.gov/32125294
https://pubmed.ncbi.nlm.nih.gov/32125294
Autor:
Ilona Seferynska, Justyna Gajkowska-Kulik, Krzysztof Lewandowski, Alina Świderska, Grzegorz Helbig, Marek Rodzaj
Publikováno v:
Polish Archives of Internal Medicine.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b4585ed943a6d7201b28e56695db7fd
https://doi.org/10.20452/pamw.15224
https://doi.org/10.20452/pamw.15224
Autor:
Julio Davila Valls, Parameswaran Hari, Martin Stork, Saurabh Chhabra, Iwona Hus, Massimo Gentile, Gergely Varga, Jan Walewski, Agnieszka Druzd-Sitek, Anna Waszczuk-Gajda, Katarzyna Krawczyk, Marek Rodzaj, Jorge J. Castillo, Lidia Usnarska-Zubkiewicz, Natalia Schutz, David H. Vesole, Ludek Pour, Ajay K. Nooka, Gabor Mikala, Stanisław Potoczek, Ravi Vij, Agnieszka Porowska, Artur Jurczyszyn, Chor Sang Chim, Mark A. Fiala
This study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c92e89a66df1d4114b40d6aa146fcc8
https://ruj.uj.edu.pl/xmlui/handle/item/263696
https://ruj.uj.edu.pl/xmlui/handle/item/263696
Autor:
Norbert Grząśko, Agnieszka Druzd-Sitek, Małgorzata Raźny, Anna Waszczuk-Gajda, Aleksandra Wędłowska, Agnieszka Szymczyk, Joanna Drozd-Sokołowska, Anna Dmoszynska, Bartłomiej Pogłódek, Aleksander Perzyński, Grzegorz Charliński, Joanna Mańko, Katarzyna Poniewierska-Jasak, Tadeusz Kubicki, Artur Jurczyszyn, Dominik Dytfeld, Mateusz Sawicki, Dariusz Jawniak, Aleksandra Gałązka, Lidia Usnarska-Zubkiewicz, Monika Długosz-Danecka, Anna Pasternak, Alina Świderska, Anna Kopińska, Iwona Hus, Marek Rodzaj
Publikováno v:
Oncology Letters
The present retrospective analysis evaluated the efficacy and safety of the VTD (bortezomib, thalidomide, dexamethasone) regimen in 205 newly-diagnosed patients with multiple myeloma (MM) eligible for high dose therapy and autologous stem cell transp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bee98fe8eecfceafc2700ffd54f75ab5
https://doi.org/10.3892/ol.2019.10929
https://doi.org/10.3892/ol.2019.10929
Autor:
Lidia Gil, Anna Kopińska, Anna Masternak, Edyta Subocz, Jarosław Biliński, Sebastian Giebel, Jadwiga Dwilewicz-Trojaczek, Piotr Kacprzyk, Renata Guzicka-Kazimierczak, Michał Górka, Karol Lis, Marek Rodzaj, Anna Waszczuk-Gajda, Krzysztof Mądry, Wanda Knopinska-Posluszny, Łukasz Bołkun, Przemyslaw Biecek, Joanna Drozd-Sokołowska, Jagoda Rytel, Tomasz Czerw, Magda Młynarczyk, D. Krochmalczyk, Rafał Machowicz, Ewa Łątka, Magdalena Dutka
Background Myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) patients, including those treated with azacitidine, are at increased risk for serious infections. The aim of our study was to identif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bba837bf5880f29afcdff488466df7e8
https://ruj.uj.edu.pl/xmlui/handle/item/125375
https://ruj.uj.edu.pl/xmlui/handle/item/125375
Autor:
David Jayabalan, Dorotea Fantl, Renata Guzicka-Kazimierczak, Grzegorz Charliński, Wanda Knopinska-Posluszny, Agnieszka Druzd-Sitek, Mark A. Fiala, Agnieszka Kopacz, Agnieszka Barchnicka, Jakub Radocha, Waldemar Sawicki, Norbert Grząśko, Roman Hájek, Iwona Hus, Michel Delforge, Anders Waage, Alessandro Gozzetti, Jorge J. Castillo, Xavier Leleu, Artur Jurczyszyn, Irit Avivi, Andrew Yee, Thomas Guerrero-Garcia, David H. Vesole, Erden Atilla, Julio Dávila, Jieqi Liu, Pawel Robak, Marek Rodzaj, Giuseppe Mele, Valentine Richez, Agoston Gyula Szabo, Anna Waszczuk-Gajda, Anna Masternak
We report a multicentre retrospective study that analysed clinical characteristics and outcomes in 117 patients with primary plasma cell leukaemia (pPCL) treated at the participating institutions between January 2006 and December 2016. The median age
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3d25c451bcce56168d21ec5846028f3
https://ruj.uj.edu.pl/xmlui/handle/item/142394
https://ruj.uj.edu.pl/xmlui/handle/item/142394
Autor:
Dariusz Jawniak, Bartłomiej Pogłódek, Agnieszka Druzd-Sitek, Andrzej Pluta, M. Razny, Anna Kopińska, Iwona Hus, Grzegorz Charliński, Alina Swiderska, Marek Rodzaj, Joanna Drozd-Sokołowska, Anna Dmoszynska, Joanna Mańko, Artur Jurczyszyn, Danuta Blonska, A. Galazka, Marek Hus, Anna Waszczuk-Gajda, Anna Pasternak, Lidia Usnarska-Zubkiewicz, Norbert Grzasko, Mateusz Sawicki
Publikováno v:
Hematological Oncology. 35:387-388
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2e3e41e9b57567e601763514f4b75e0
https://doi.org/10.1002/hon.2439_151
https://doi.org/10.1002/hon.2439_151
Autor:
Jaroslaw Piszcz, Marek Hus, Małgorzata Raźny, Malgorzata Calbecka, Alina Urbanowicz, Ewa Żuk, Ilona Seferynska, Slawomira Kyrcz-Krzemien, Alina Swiderska, Marek Rodzaj, Grzegorz Helbig, Andrzej Moskwa
Publikováno v:
Cancer Chemotherapy and Pharmacology
To the Editor, The exquisite response to imatinib mesylate in patients with chronic eosinophilic leukaemia (CEL) harbouring the FIP1L1-PDGFRα (F/P) fusion transcript has been well documented [1–4]. In the up-to-date largest multicentre study, all
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9155801b57d224e3e82599d6773f79ec
https://doi.org/10.1007/s00280-011-1582-3
https://doi.org/10.1007/s00280-011-1582-3